Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $25.71 Average Target Price from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been given an average recommendation of “Moderate Buy” by the nine research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $25.7143.

A number of research firms have recently weighed in on DAWN. TD Cowen started coverage on Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating and a $34.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. JPMorgan Chase & Co. raised their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Piper Sandler upped their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th.

Day One Biopharmaceuticals Price Performance

DAWN opened at $11.70 on Friday. The firm has a 50 day simple moving average of $10.55 and a 200 day simple moving average of $8.70. Day One Biopharmaceuticals has a fifty-two week low of $5.64 and a fifty-two week high of $13.20. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -7.70 and a beta of -1.26.

Insider Buying and Selling

In other news, CFO Charles N. York II sold 6,065 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the transaction, the chief financial officer directly owned 312,025 shares of the company’s stock, valued at $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeremy Bender sold 15,459 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the sale, the chief executive officer owned 204,603 shares of the company’s stock, valued at approximately $2,373,394.80. This represents a 7.02% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 36,461 shares of company stock valued at $422,948. 6.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently modified their holdings of DAWN. Mirae Asset Global Investments Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after buying an additional 1,029 shares during the period. Los Angeles Capital Management LLC increased its position in shares of Day One Biopharmaceuticals by 1.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 100,314 shares of the company’s stock worth $935,000 after acquiring an additional 1,425 shares in the last quarter. Perkins Capital Management Inc. raised its holdings in shares of Day One Biopharmaceuticals by 2.1% during the fourth quarter. Perkins Capital Management Inc. now owns 84,000 shares of the company’s stock worth $783,000 after acquiring an additional 1,750 shares during the period. CWM LLC lifted its position in Day One Biopharmaceuticals by 32.4% in the 4th quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after acquiring an additional 2,051 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in Day One Biopharmaceuticals by 12.9% in the 2nd quarter. ProShare Advisors LLC now owns 18,545 shares of the company’s stock valued at $121,000 after acquiring an additional 2,121 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.